CD163 and neoplasm: We evaluated the expression of CD45, CD14, CD163, ARG1, CD4, FOXP3, PRF1, GMZB, and IL10 mRNAs in primary tumor samples taken at diagnosis from 41 patients with metastatic NB >18 months at diagnosis.